ATE68352T1 - Methode zur behandlung der eisenuebersaettigung. - Google Patents

Methode zur behandlung der eisenuebersaettigung.

Info

Publication number: ATE68352T1
Authority: AT; Austria
Prior art keywords: iron; supersaturation; treatment; mammal; red blood
Prior art date: 1986-11-21

Application number

AT87310300T

Other languages

English (en)

Inventor

John William Adamson

Michael Richard Downing

Joseph Wetherill Eschbach

Joan Christine Egrie

Original Assignee

Kirin Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-21

Filing date

1987-11-20

Publication date

1991-11-15

1987-11-20 Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc

1991-11-15 Application granted granted Critical

1991-11-15 Publication of ATE68352T1 publication Critical patent/ATE68352T1/de

Links

XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 6
229910052742 iron Inorganic materials 0.000 title abstract 3
241000124008 Mammalia Species 0.000 abstract 3
210000003743 erythrocyte Anatomy 0.000 abstract 2
102000003951 Erythropoietin Human genes 0.000 abstract 1
108090000394 Erythropoietin Proteins 0.000 abstract 1
206010065973 Iron Overload Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940105423 erythropoietin Drugs 0.000 abstract 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Treatment Of Water By Oxidation Or Reduction (AREA)
Manufacture Of Iron (AREA)
Chemical Treatment Of Metals (AREA)
Peptides Or Proteins (AREA)
Hydrogen, Water And Hydrids (AREA)
Treatment Of Water By Ion Exchange (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compounds Of Iron (AREA)

AT87310300T 1986-11-21 1987-11-20 Methode zur behandlung der eisenuebersaettigung. ATE68352T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/933,495 US5013718A (en)	1986-11-21	1986-11-21	Method for treating iron overload using EPO
EP87310300A EP0269394B1 (de)	1986-11-21	1987-11-20	Methode zur Behandlung der Eisenübersättigung

Publications (1)

Publication Number	Publication Date
ATE68352T1 true ATE68352T1 (de)	1991-11-15

Family

ID=25464076

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT87310300T ATE68352T1 (de)	1986-11-21	1987-11-20	Methode zur behandlung der eisenuebersaettigung.

Country Status (16)

Country	Link
US (1)	US5013718A (de)
EP (1)	EP0269394B1 (de)
JP (1)	JPH0692316B2 (de)
KR (1)	KR950009100B1 (de)
AT (1)	ATE68352T1 (de)
AU (1)	AU602028B2 (de)
CA (1)	CA1322165C (de)
DE (1)	DE3773852D1 (de)
DK (1)	DK167650B1 (de)
ES (1)	ES2039252T3 (de)
GR (1)	GR3003254T3 (de)
IE (1)	IE60865B1 (de)
IL (1)	IL84275A (de)
NZ (1)	NZ222432A (de)
PT (1)	PT86187B (de)
WO (1)	WO1988003808A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO881507D0 (no) *	1987-04-10	1988-04-07	Ortho Pharma Corp	Fremgangsmaate for forhoeyning av hematokritnivaaet til et normalt pattedyr.
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US6012450A (en) *	1993-01-29	2000-01-11	Aradigm Corporation	Intrapulmonary delivery of hematopoietic drug
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
ATE251912T1 (de)	1994-11-03	2003-11-15	Roche Diagnostics Gmbh	Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
CA2216443A1 (en)	1995-03-31	1996-10-03	Aradigm Corporation	Intrapulmonary delivery of hematopoietic drug
TW586933B (en) *	1996-06-20	2004-05-11	Chugai Pharmaceutical Co Ltd	Compositions for treating liver-complaints using EPO
US5952226A (en) *	1996-11-05	1999-09-14	Modex Therapeutiques	Hypoxia responsive EPO producing cells
EP0965349A1 (de) *	1998-06-18	1999-12-22	Roche Diagnostics GmbH	Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
AR019025A1 (es)	1998-04-09	2001-12-26	Roche Diagnostics Gmbh	Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
US6210924B1 (en)	1998-08-11	2001-04-03	Amgen Inc.	Overexpressing cyclin D 1 in a eukaryotic cell line
DE19857609A1 (de) *	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
WO2001035095A2 (en) *	1999-11-12	2001-05-17	Rothenberg Barry E	Diagnostic test for hemochromatosis
US7160855B2 (en) *	2002-03-14	2007-01-09	Children's Hospital & Research Center At Oakland	Enhancement of iron chelation therapy
DE10234192B4 (de)	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
DE60332358D1 (de) *	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
WO2008065372A2 (en)	2006-11-28	2008-06-05	Nautilus Biotech, S.A.	Modified erythropoietin polypeptides and uses thereof for treatment
US10694962B2 (en)	2011-06-13	2020-06-30	Cedars-Sinai Medical Center	Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
WO2012174157A1 (en) *	2011-06-13	2012-12-20	Cedars-Sinai Medical Center	Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
FR3037592B1 (fr)	2015-06-18	2017-06-09	Michelin & Cie	Pneumatique pourvu d'une bande de roulement comprenant un elastomere dienique et un systeme d'elastomeres thermoplastiques
CA3193654A1 (en)	2020-10-02	2022-04-07	Jasbir S. Seehra	Methods of using activin receptor type ii variants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0686480B2 (ja) *	1983-02-21	1994-11-02	雪印乳業株式会社	エリスロポエチン製造用モノクローナル抗体
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) *	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
US4667016A (en) *	1985-06-20	1987-05-19	Kirin-Amgen, Inc.	Erythropoietin purification

1986
- 1986-11-21 US US06/933,495 patent/US5013718A/en not_active Expired - Lifetime
1987
- 1987-10-19 AU AU81794/87A patent/AU602028B2/en not_active Expired
- 1987-10-19 KR KR1019880700864A patent/KR950009100B1/ko not_active Expired - Lifetime
- 1987-10-19 WO PCT/US1987/002673 patent/WO1988003808A1/en not_active Ceased
- 1987-10-25 IL IL84275A patent/IL84275A/xx not_active IP Right Cessation
- 1987-11-03 NZ NZ222432A patent/NZ222432A/xx unknown
- 1987-11-18 IE IE311387A patent/IE60865B1/en not_active IP Right Cessation
- 1987-11-18 CA CA000552139A patent/CA1322165C/en not_active Expired - Lifetime
- 1987-11-19 JP JP62293071A patent/JPH0692316B2/ja not_active Expired - Lifetime
- 1987-11-20 AT AT87310300T patent/ATE68352T1/de not_active IP Right Cessation
- 1987-11-20 EP EP87310300A patent/EP0269394B1/de not_active Expired - Lifetime
- 1987-11-20 ES ES198787310300T patent/ES2039252T3/es not_active Expired - Lifetime
- 1987-11-20 PT PT86187A patent/PT86187B/pt active IP Right Revival
- 1987-11-20 DE DE8787310300T patent/DE3773852D1/de not_active Expired - Lifetime
1988
- 1988-07-21 DK DK407488A patent/DK167650B1/da not_active IP Right Cessation
1991
- 1991-12-02 GR GR91401882T patent/GR3003254T3/el unknown

Also Published As

Publication number	Publication date
DK407488D0 (da)	1988-07-21
NZ222432A (en)	1990-07-26
DE3773852D1 (de)	1991-11-21
KR950009100B1 (ko)	1995-08-14
KR890700032A (ko)	1989-03-02
PT86187B (pt)	1990-11-07
EP0269394A3 (en)	1988-09-14
ES2039252T3 (es)	1993-09-16
JPH0692316B2 (ja)	1994-11-16
IE60865B1 (en)	1994-08-24
AU8179487A (en)	1988-06-16
PT86187A (en)	1987-12-01
GR3003254T3 (en)	1993-02-17
DK167650B1 (da)	1993-12-06
IL84275A (en)	1993-04-04
DK407488A (da)	1988-07-21
EP0269394B1 (de)	1991-10-16
CA1322165C (en)	1993-09-14
JPS63159322A (ja)	1988-07-02
EP0269394A2 (de)	1988-06-01
US5013718A (en)	1991-05-07
WO1988003808A1 (en)	1988-06-02
IE873113L (en)	1988-05-21
AU602028B2 (en)	1990-09-27

Similar Documents

Publication	Publication Date	Title
ATE68352T1 (de)	1991-11-15	Methode zur behandlung der eisenuebersaettigung.
RU93052390A (ru)	1996-10-10	Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
PT87086A (pt)	1988-04-01	Active specific immune suppression
NO880929L (no)	1988-03-02	Produksjon og bruk av il-6.
NO880022L (no)	1988-01-05	Fremstilling av m-csf.
NO881819D0 (no)	1988-04-26	Forenklet fremgangsmaate for fremstilling av humane lymfokinaktivate drepeceller.
EP0179390A3 (de)	1987-07-29	L-Lysin- und L-Histidinpyruvat
FR2314729A1 (fr)	1977-01-14	Solution injectable d'hemoglobine ne renfermant pas de stroma et procede de sa preparation
ZA869175B (en)	1987-08-26	Method for enhancement of healing of epithelial wounds in mammals
PH23901A (en)	1989-12-18	Treatment of diabetes using fluoxetine
ATE70978T1 (de)	1992-01-15	Zusammensetzung zur erhoehung des haematokrits bei einem normalen saeugetier.
FR2559781B3 (fr)	1986-05-30	Nouveau vecteur plasmidique hybride de e. coli conferant le pouvoir de faire fermenter le saccharose et son procede de preparation
ATA147676A (de)	1978-01-15	Verfahren zur herstellung von reiner traubensaure und von mesoweinsaure
OA09455A (fr)	1992-11-15	Nouveaux polyols furanniques, utilisation de ceux-ci comme polyols dans la formation de polyuréthannes, polyuréthannes ainsi obtenus et leur procédé de préparation.
SE429091B (sv)	1983-08-15	Forfarande for behandling av cellprotein for att reducera halten nukleinsyra i cellerna
DK299585D0 (da)	1985-07-02	Fremgangsmaade til behandling af syreholdige afgangsgasser
PH23658A (en)	1989-09-27	Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
FR2558481B1 (fr)	1988-11-04	Procede de preparation de l'acide 4-amino-3-hydroxybutyrique optiquement actif
FR2549390B1 (fr)	1988-05-20	Procede de retention d'un corps dissous dans une solution
DE3780702D1 (de)	1992-09-03	Verwendung von etodolac zur senkung des blutgehalts an harnsaeure.
SU568633A1 (ru)	1977-08-15	Способ получени серосодержащих эфиров 2,4-дихлорфеноксиуксусной кислоты
JPS6480286A (en)	1989-03-27	Method for purifying enzyme
ES428172A1 (es)	1976-11-16	Un procedimiento para preparar acido 5-pivaloiloxi-5-(1-fe-niletil)-barbiturico.
GB1527479A (en)	1978-10-04	Acid addition salts of d-(+)-1-(3-hydroxyphenyl)-2-aminopropane and their manufacture and use
AU7931487A (en)	1988-04-14	Therapeutic treatment of abnormal cell growth with follicle regulatory protein

Legal Events

Date	Code	Title	Description
1992-07-15	UEP	Publication of translation of european patent specification
2008-02-15	EELA	Cancelled due to lapse of time